Cymbalta Pain Advisory Committee Could Hinge On Hepatotoxicity Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
The new indication for Lilly's SNRI would expose a much larger patient population to the risk of liver injury. The FDA reviewer and his supervisors disagree about how to handle the concern.
You may also be interested in...
Cymbalta Adds Musculoskeletal Pain Claim Despite Advisory Committee Concerns
Label for duloxetine's new use emphasizes that efficacy was shown only in patients with chronic lower back pain and osteoarthritis.
Cymbalta Adds Musculoskeletal Pain Claim Despite Advisory Committee Concerns
Label for duloxetine's new use emphasizes that efficacy was shown only in patients with chronic lower back pain and osteoarthritis.
Cymbalta Chronic Pain Label: FDA Expresses Faith In Physicians' Judgment
FDA may place more faith in physician diligence to read updated labeling as it manages the risk for Eli Lilly's Cymbalta in some chronic pain indications